Bioterrorism: A Billion-Plus for Countermeasures, But Also New Strings
This article was originally published in Start Up
Executive Summary
The new US bioterrorism bill will direct hundreds of millions of dollars toward bolstering the US pharmaceutical stockpile. At the same time, it imposes reporting and other obligations on companies. On the other hand, some regulatory burdens on companies will be eased. And because FDA may now find now in an unusual dual position with respect to risk taking--promoting industry while at the same time regulating--it could create a different dynamic with companies.You may also be interested in...
Science Matters: With Ferroptosis, Cancer Drug Developers Can Strike While Iron Is Hot
A series of basic research insights around the cell death process called ferroptosis could form the underpinnings of a new class of treatments aimed at drug resistant tumors.
Science Matters: Glimmers Of Hope For Treating ALS
Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.
Science Matters: Merck Joins Crowded NASH Race As Several Data Readouts Loom
No NASH treatments are on the market yet, but Phase III data readouts are emerging, mid-stage drugs are demonstrating their capabilities and combinations are in view.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: